Key Takeaways
- Qualcomm (QCOM) surged 9.5% after announcing a multi-generational pact with Amazon (AMZN) to build AI data center infrastructure, including a warrant for Amazon to purchase up to 25 million shares.
- Verizon (VZ) and Corning (GLW) signed a multi-billion dollar agreement for 80 million miles of optical fiber to support nationwide broadband and AI backbone needs through 2032.
- Novartis (NVS) shares tumbled over 12% after its Phase 3 Lp(a)HORIZON study for the cardiovascular drug pelacarsen missed its primary endpoint.
- Geopolitical tensions escalated as Iranian state media claimed the military downed a U.S. MQ-1 drone over the Strait of Hormuz; U.S. officials have yet to confirm the report.
- The European Commission approved Ukraine's request to use €3.2 billion from an EU loan to purchase U.S. Patriot interceptor missiles ahead of the winter season.
Tech & AI Infrastructure: Qualcomm and Amazon Lead Gains
Qualcomm (QCOM) shares jumped nearly 10% in early trading following the announcement of a landmark collaboration with Amazon Web Services (AWS). The partnership focuses on developing customized silicon and high-speed optical connectivity solutions tailored for massive AI inference workloads. As part of the agreement, Qualcomm will issue a warrant to Amazon (AMZN) for up to 25 million shares, with a strike price of $161.26, signaling a long-term strategic alignment between the two giants.
Simultaneously, Verizon (VZ) and Corning (GLW) announced a massive supply deal to secure the "physical foundation of the AI economy." Corning will provide over 80 million miles of high-density optical fiber through 2032. This agreement is designed to accelerate Verizon's broadband expansion to 40-50 million passings while building the long-haul connectivity required by AI hyperscalers.
Healthcare Setbacks: Novartis and Ionis Under Pressure
The pharmaceutical sector faced a sharp sell-off as Novartis (NVS) reported that its highly anticipated Phase 3 Lp(a)HORIZON study failed to meet its primary endpoint. The drug, pelacarsen, developed in partnership with Ionis Pharmaceuticals (IONS), successfully lowered lipoprotein(a) levels but did not translate that reduction into a significant decrease in major cardiovascular events. Novartis shares fell 12.6%, while Ionis dropped 10.9% on the news, which analysts suggest raises the "burden of proof" for similar therapies from competitors like Amgen (AMGN).
Geopolitical Friction: Drone Claims and Defense Spending
Tensions in the Middle East spiked Tuesday after the IRGC-affiliated Fars News Agency reported that Iranian air defense units targeted and downed a U.S. drone near Bandar Abbas. While Iranian state media identified the craft as an MQ-1, U.S. Central Command has not confirmed any loss of aircraft. This development comes amid a broader regional "exclusion zone" threat from Tehran, which has already pushed oil prices toward the $100 per barrel mark.
In Europe, the European Commission cleared a €3.2 billion tranche for Ukraine to procure Patriot interceptor missiles from the United States. The funding, part of a larger €90 billion EU loan, is intended to shield Ukrainian infrastructure from ballistic missile attacks during the upcoming winter. This move underscores the continued reliance on U.S. defense manufacturing as European production lines remain at capacity.
Market Movers: Pre-Market Highlights
- Intel (INTC) gained 5.0% following an upgrade to "Outperform" at Northland, as the market reacted positively to its ongoing turnaround efforts.
- Tesla (TSLA) edged up 0.4% after its "FSD Supervised" software received regulatory approval for use in Slovenia.
- Peloton (PTON) slid 5.9% after Morgan Stanley downgraded the stock to "Underweight," citing concerns over long-term growth sustainability.
- Paramount Skydance (PSKY) extended its debt tender and exchange offers to September 18 as it continues to navigate the complexities of its $111 billion merger with Warner Bros. Discovery.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.